Clinical Trial Update: Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial evaluating selumetinib with docetaxel in advanced gastric adenocarcinoma patients with MEK signature or RAS alterations as second-line …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Selumetinib (selumetinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED